Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 223.62M +59.3% |
| Revenue (ttm) | n/a |
| Net Income | -22.47M |
| EPS | -1.58 |
| Shares Out | 14.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,590 |
| Open | 15.12 |
| Previous Close | 15.40 |
| Day's Range | 15.10 - 15.61 |
| 52-Week Range | 7.78 - 34.10 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 57.00 (+274.14%) |
| Est. Earnings | Nov 13, 2026 |
About GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GLSI stock is "Strong Buy." The 12-month stock price target is $57.0, which is an increase of 274.14% from the latest price.
News
Greenwich LifeSciences Quarterly report: Q2 2026
Greenwich LifeSciences has published its Q2 2026 quarterly earnings report on August 11, 2026.
Greenwich LifeSciences extends lock-up of directors and officers to 2027
Greenwich LifeSciences (GLSI)’ Board of Directors has extended the lock-up of the shares owned by the company’s directors, officers, and existing pre-IPO investors to January 31, 2027 which is approxi...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich receives regulatory approval to expand Flamingo-01 in the U.K.
Greenwich LifeSciences (GLSI) announced the regulatory approval to expand FLAMINGO-01 into the U.K. The Company’s application to expand FLAMINGO-01 into the UK has been formally approved by UK regulat...
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences price target raised to $69 from $50 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Greenwich LifeSciences (GLSI) to $69 from $50 and keeps a Buy rating on the shares. Greenwich LifeSciences received FDA…
Greenwich LifeSciences provides clinical and financial updates on Flamingo-01
Greenwich LifeSciences (GLSI) provided the following clinical updates on FLAMINGO-01. The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification. On December 22...
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich announces European approval for FLAMINGO-01 population combination
Greenwich LifeSciences (GLSI) provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe. The company previously announced that US clinical si...
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences Quarterly report: Q1 2026
Greenwich LifeSciences has published its Q1 2026 quarterly earnings report on June 4, 2026.
Greenwich LifeSciences presents FLAMINGO-01 data at ASCO
Greenwich LifeSciences (GLSI) presents the published abstract and poster from the ASCO annual meeting. The abstract is shown below. This is the second abstract and poster presented jointly with the…
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences Annual report: Q4 2025
Greenwich LifeSciences has published its Q4 2025 annual report on June 1, 2026.
Greenwich LifeSciences provides update on 10-K filing
Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. “The Form 10-K for the fiscal year ending December 31, 2025,…
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinic...
Greenwich LifeSciences says Form 10-K ‘still being audited’
Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025…
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences receives noncompliance notification from Nasdaq
Greenwich LifeSciences announced that on April 16, the company received notification from Nasdaq notifying the company that, because it has not yet filed its annual report on Form 10-K for…
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026
Greenwich LifeSciences (GLSI) focused on its Phase III clinical trial, FLAMINGO-01 presents the published abstract and poster from the AACR Meeting 2026. This is the first abstract and poster presente...
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...